Better Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta Therapeutics, Inc.
You might think that a biotech with a recent FDA regulatory win would automatically be a better investing pick than another biotech with no approved products. That's sometimes the case, but not always. Sarepta Therapeutics (NASDAQ: SRPT) now has an FDA-approved drug, while Alnylam Pharmaceuticals (NASDAQ: ALNY) doesn't and even recently experienced major clinical setback. But which of these two biotech stocks is actually the better buy?